ID   EFNB1_HUMAN             Reviewed;         346 AA.
AC   P98172; D3DVU0;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   28-JUN-2023, entry version 210.
DE   RecName: Full=Ephrin-B1;
DE   AltName: Full=EFL-3;
DE   AltName: Full=ELK ligand;
DE            Short=ELK-L;
DE   AltName: Full=EPH-related receptor tyrosine kinase ligand 2;
DE            Short=LERK-2;
DE   Contains:
DE     RecName: Full=Ephrin-B1 C-terminal fragment {ECO:0000303|PubMed:16930449};
DE              Short=Ephrin-B1 CTF {ECO:0000303|PubMed:16930449};
DE   Contains:
DE     RecName: Full=Ephrin-B1 intracellular domain {ECO:0000303|PubMed:16930449};
DE              Short=Ephrin-B1 ICD {ECO:0000303|PubMed:16930449};
DE   Flags: Precursor;
GN   Name=EFNB1; Synonyms=EFL3, EPLG2, LERK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.
RC   TISSUE=Placenta;
RX   PubMed=8070404; DOI=10.1002/j.1460-2075.1994.tb06685.x;
RA   Beckmann M.P., Cerretti D.P., Baum P., Vanden Bos T., James L., Farrah T.,
RA   Kozlosky C., Hollingsworth T., Shilling H., Maraskovsky E., Fletcher F.A.,
RA   Lhotak V., Pawson T., Lyman S.D.;
RT   "Molecular characterization of a family of ligands for eph-related tyrosine
RT   kinase receptors.";
RL   EMBO J. 13:3757-3762(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND PHOSPHORYLATION.
RX   PubMed=7973638; DOI=10.1126/science.7973638;
RA   Davis S., Gale N.W., Aldrich T.H., Maisonpierre P.C., Lhotak V., Pawson T.,
RA   Goldfarb M., Yancopoulos G.D.;
RT   "Ligands for EPH-related receptor tyrosine kinases that require membrane
RT   attachment or clustering for activity.";
RL   Science 266:816-819(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Fletcher F.A., Huebner K., Shaffer L.G., Monaco A., Mueller U.,
RA   Kozlosky C., Druck T., Simoneaux D.K., Fairweather N., Chelly J.,
RA   Cerretti D.P., Belmont J.W., Beckmann M.P., Lyman S.D.;
RT   "Assignment of the human Elk ligand gene, EPLG2, to chromosome region
RT   Xq12.";
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 28-42.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [8]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH GRIP1 AND GRIP2.
RC   TISSUE=Fetal brain;
RX   PubMed=10197531; DOI=10.1016/s0896-6273(00)80706-0;
RA   Brueckner K., Pablo Labrador J., Scheiffele P., Herb A., Seeburg P.H.,
RA   Klein R.;
RT   "EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft
RT   membrane microdomains.";
RL   Neuron 22:511-524(1999).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, PROTEOLYTIC CLEAVAGE, NUCLEAR LOCALIZATION
RP   SIGNAL, AND MUTAGENESIS OF 260-VAL--THR-273 AND 344-TYR--VAL-346.
RX   PubMed=16930449; DOI=10.1186/1750-1326-1-2;
RA   Tomita T., Tanaka S., Morohashi Y., Iwatsubo T.;
RT   "Presenilin-dependent intramembrane cleavage of ephrin-B1.";
RL   Mol. Neurodegener. 1:2-2(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   INTERACTION WITH TLE1.
RX   PubMed=21429299; DOI=10.5483/bmbrep.2011.44.3.199;
RA   Kamata T., Bong Y.S., Mood K., Park M.J., Nishanian T.G., Lee H.S.;
RT   "EphrinB1 interacts with the transcriptional co-repressor Groucho/xTLE4.";
RL   BMB Rep. 44:199-204(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-281 AND SER-287, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   VARIANTS CFNS LEU-54 AND ILE-111.
RX   PubMed=15124102; DOI=10.1086/421532;
RA   Wieland I., Jakubiczka S., Muschke P., Cohen M., Thiele H., Gerlach K.L.,
RA   Adams R.H., Wieacker P.;
RT   "Mutations of the ephrin-B1 gene cause craniofrontonasal syndrome.";
RL   Am. J. Hum. Genet. 74:1209-1215(2004).
RN   [16]
RP   VARIANTS CFNS THR-62; SER-98; PRO-115; HIS-119; THR-119; SER-151; VAL-151;
RP   PRO-155; ILE-158 AND VAL-158, AND VARIANT HIS-154.
RX   PubMed=15166289; DOI=10.1073/pnas.0402819101;
RA   Twigg S.R.F., Kan R., Babbs C., Bochukova E.G., Robertson S.P., Wall S.A.,
RA   Morriss-Kay G.M., Wilkie A.O.M.;
RT   "Mutations of ephrin-B1 (EFNB1), a marker of tissue boundary formation,
RT   cause craniofrontonasal syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:8652-8657(2004).
RN   [17]
RP   VARIANTS CFNS ARG-27; LEU-54; SER-119; HIS-119; ALA-137; PHE-138; SER-151;
RP   SER-153; TYR-153 AND ARG-182.
RX   PubMed=15959873; DOI=10.1002/humu.20193;
RA   Wieland I., Reardon W., Jakubiczka S., Franco B., Kress W.,
RA   Vincent-Delorme C., Thierry P., Edwards M., Koenig R., Rusu C.,
RA   Schweiger S., Thompson E., Tinschert S., Stewart F., Wieacker P.;
RT   "Twenty-six novel EFNB1 mutations in familial and sporadic
RT   craniofrontonasal syndrome (CFNS).";
RL   Hum. Mutat. 26:113-118(2005).
CC   -!- FUNCTION: Cell surface transmembrane ligand for Eph receptors, a family
CC       of receptor tyrosine kinases which are crucial for migration, repulsion
CC       and adhesion during neuronal, vascular and epithelial development
CC       (PubMed:8070404, PubMed:7973638). Binding to Eph receptors residing on
CC       adjacent cells leads to contact-dependent bidirectional signaling into
CC       neighboring cells (PubMed:8070404, PubMed:7973638). Shows high affinity
CC       for the receptor tyrosine kinase EPHB1/ELK (PubMed:8070404,
CC       PubMed:7973638). Can also bind EPHB2 and EPHB3 (PubMed:8070404). Binds
CC       to, and induces collapse of, commissural axons/growth cones in vitro
CC       (By similarity). May play a role in constraining the orientation of
CC       longitudinally projecting axons (By similarity).
CC       {ECO:0000250|UniProtKB:P52795, ECO:0000269|PubMed:7973638,
CC       ECO:0000269|PubMed:8070404}.
CC   -!- SUBUNIT: Interacts (via PDZ-binding motif) with GRIP1 and GRIP2 (via
CC       PDZ domain 6) (PubMed:10197531). Interacts with TLE1 (PubMed:21429299).
CC       The intracellular domain peptide interacts with ZHX2; the interaction
CC       enhances ZHX2 transcriptional repression activity (By similarity).
CC       {ECO:0000250|UniProtKB:P52795, ECO:0000269|PubMed:10197531,
CC       ECO:0000269|PubMed:21429299}.
CC   -!- INTERACTION:
CC       P98172; Q86W74-2: ANKRD46; NbExp=3; IntAct=EBI-538287, EBI-12109402;
CC       P98172; P04626: ERBB2; NbExp=11; IntAct=EBI-538287, EBI-641062;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10197531,
CC       ECO:0000269|PubMed:7973638}; Single-pass type I membrane protein
CC       {ECO:0000255}. Membrane raft {ECO:0000269|PubMed:10197531}. Note=May
CC       recruit GRIP1 and GRIP2 to membrane raft domains.
CC       {ECO:0000269|PubMed:10197531}.
CC   -!- SUBCELLULAR LOCATION: [Ephrin-B1 C-terminal fragment]: Cell membrane
CC       {ECO:0000269|PubMed:16930449}; Single-pass type I membrane protein
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Ephrin-B1 intracellular domain]: Nucleus
CC       {ECO:0000269|PubMed:16930449}. Note=Colocalizes with ZHX2 in the
CC       nucleus. {ECO:0000250|UniProtKB:P52795}.
CC   -!- TISSUE SPECIFICITY: Widely expressed (PubMed:8070404, PubMed:7973638).
CC       Detected in both neuronal and non-neuronal tissues (PubMed:8070404,
CC       PubMed:7973638). Seems to have particularly strong expression in
CC       retina, sciatic nerve, heart and spinal cord (PubMed:7973638).
CC       {ECO:0000269|PubMed:7973638, ECO:0000269|PubMed:8070404}.
CC   -!- INDUCTION: Up-regulated in response to TNF.
CC       {ECO:0000269|PubMed:8070404}.
CC   -!- PTM: Inducible phosphorylation of tyrosine residues in the cytoplasmic
CC       domain. {ECO:0000269|PubMed:7973638}.
CC   -!- PTM: Proteolytically processed. The ectodomain is cleaved, probably by
CC       a metalloprotease, to produce a membrane-tethered C-terminal fragment.
CC       This fragment is then further processed by the gamma-secretase complex
CC       to yield a soluble intracellular domain peptide which can translocate
CC       to the nucleus. The intracellular domain peptide is highly labile
CC       suggesting that it is targeted for degradation by the proteasome.
CC       {ECO:0000269|PubMed:16930449}.
CC   -!- DISEASE: Craniofrontonasal syndrome (CFNS) [MIM:304110]: X-linked
CC       inherited syndrome characterized by hypertelorism, coronal synostosis
CC       with brachycephaly, downslanting palpebral fissures, clefting of the
CC       nasal tip, joint anomalies, longitudinally grooved fingernails and
CC       other digital anomalies. {ECO:0000269|PubMed:15124102,
CC       ECO:0000269|PubMed:15166289, ECO:0000269|PubMed:15959873}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the ephrin family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00884}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U09304; AAA53093.1; -; mRNA.
DR   EMBL; L37361; AAA52369.1; -; mRNA.
DR   EMBL; U09303; AAB41127.1; -; mRNA.
DR   EMBL; AL136092; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471132; EAX05370.1; -; Genomic_DNA.
DR   EMBL; CH471132; EAX05371.1; -; Genomic_DNA.
DR   EMBL; BC016649; AAH16649.1; -; mRNA.
DR   EMBL; BC052979; AAH52979.1; -; mRNA.
DR   CCDS; CCDS14391.1; -.
DR   PIR; S46993; S46993.
DR   RefSeq; NP_004420.1; NM_004429.4.
DR   PDB; 6THG; X-ray; 4.07 A; C/D/F/H/J=29-167.
DR   PDBsum; 6THG; -.
DR   AlphaFoldDB; P98172; -.
DR   SMR; P98172; -.
DR   BioGRID; 108267; 262.
DR   CORUM; P98172; -.
DR   IntAct; P98172; 44.
DR   MINT; P98172; -.
DR   STRING; 9606.ENSP00000204961; -.
DR   GlyCosmos; P98172; 1 site, No reported glycans.
DR   GlyGen; P98172; 10 sites, 2 O-linked glycans (9 sites).
DR   iPTMnet; P98172; -.
DR   PhosphoSitePlus; P98172; -.
DR   BioMuta; EFNB1; -.
DR   DMDM; 1706668; -.
DR   EPD; P98172; -.
DR   jPOST; P98172; -.
DR   MassIVE; P98172; -.
DR   MaxQB; P98172; -.
DR   PaxDb; P98172; -.
DR   PeptideAtlas; P98172; -.
DR   ProteomicsDB; 57806; -.
DR   Antibodypedia; 43761; 622 antibodies from 36 providers.
DR   DNASU; 1947; -.
DR   Ensembl; ENST00000204961.5; ENSP00000204961.4; ENSG00000090776.6.
DR   GeneID; 1947; -.
DR   KEGG; hsa:1947; -.
DR   MANE-Select; ENST00000204961.5; ENSP00000204961.4; NM_004429.5; NP_004420.1.
DR   UCSC; uc004dxd.5; human.
DR   AGR; HGNC:3226; -.
DR   CTD; 1947; -.
DR   DisGeNET; 1947; -.
DR   GeneCards; EFNB1; -.
DR   HGNC; HGNC:3226; EFNB1.
DR   HPA; ENSG00000090776; Low tissue specificity.
DR   MalaCards; EFNB1; -.
DR   MIM; 300035; gene.
DR   MIM; 304110; phenotype.
DR   neXtProt; NX_P98172; -.
DR   OpenTargets; ENSG00000090776; -.
DR   Orphanet; 1520; Craniofrontonasal dysplasia.
DR   PharmGKB; PA27661; -.
DR   VEuPathDB; HostDB:ENSG00000090776; -.
DR   eggNOG; KOG3858; Eukaryota.
DR   GeneTree; ENSGT00940000160128; -.
DR   HOGENOM; CLU_072080_0_0_1; -.
DR   InParanoid; P98172; -.
DR   OMA; YKLYMVR; -.
DR   OrthoDB; 5402021at2759; -.
DR   PhylomeDB; P98172; -.
DR   PathwayCommons; P98172; -.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P98172; -.
DR   SIGNOR; P98172; -.
DR   BioGRID-ORCS; 1947; 13 hits in 786 CRISPR screens.
DR   ChiTaRS; EFNB1; human.
DR   GeneWiki; EFNB1; -.
DR   GenomeRNAi; 1947; -.
DR   Pharos; P98172; Tbio.
DR   PRO; PR:P98172; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P98172; protein.
DR   Bgee; ENSG00000090776; Expressed in ventricular zone and 124 other tissues.
DR   Genevisible; P98172; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProt.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0045202; C:synapse; ISS:UniProtKB.
DR   GO; GO:0046875; F:ephrin receptor binding; IDA:UniProt.
DR   GO; GO:0097027; F:ubiquitin-protein transferase activator activity; IDA:UniProt.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0009880; P:embryonic pattern specification; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:2000785; P:regulation of autophagosome assembly; IDA:UniProt.
DR   GO; GO:0031295; P:T cell costimulation; IEA:Ensembl.
DR   GO; GO:0042098; P:T cell proliferation; IEA:Ensembl.
DR   CDD; cd10426; Ephrin-B_Ectodomain; 1.
DR   Gene3D; 2.60.40.420; Cupredoxins - blue copper proteins; 1.
DR   InterPro; IPR008972; Cupredoxin.
DR   InterPro; IPR031328; Ephrin.
DR   InterPro; IPR034255; Ephrin-B_Ecto.
DR   InterPro; IPR019765; Ephrin_CS.
DR   InterPro; IPR001799; Ephrin_RBD.
DR   PANTHER; PTHR11304; EPHRIN; 1.
DR   PANTHER; PTHR11304:SF17; EPHRIN-B1; 1.
DR   Pfam; PF00812; Ephrin; 1.
DR   PRINTS; PR01347; EPHRIN.
DR   SUPFAM; SSF49503; Cupredoxins; 1.
DR   PROSITE; PS01299; EPHRIN_RBD_1; 1.
DR   PROSITE; PS51551; EPHRIN_RBD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Craniosynostosis; Developmental protein;
KW   Differentiation; Direct protein sequencing; Disease variant;
KW   Disulfide bond; Glycoprotein; Membrane; Neurogenesis; Nucleus;
KW   Phosphoprotein; Reference proteome; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..27
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           28..346
FT                   /note="Ephrin-B1"
FT                   /id="PRO_0000008387"
FT   CHAIN           218..346
FT                   /note="Ephrin-B1 C-terminal fragment"
FT                   /evidence="ECO:0000305"
FT                   /id="PRO_0000445791"
FT   CHAIN           260..346
FT                   /note="Ephrin-B1 intracellular domain"
FT                   /evidence="ECO:0000305"
FT                   /id="PRO_0000445792"
FT   TOPO_DOM        28..237
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        238..258
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        259..346
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          30..164
FT                   /note="Ephrin RBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00884"
FT   REGION          169..228
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          263..294
FT                   /note="Interaction with ZHX2"
FT                   /evidence="ECO:0000250|UniProtKB:P52795"
FT   MOTIF           260..273
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:16930449"
FT   MOTIF           344..346
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        170..200
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         287
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   CARBOHYD        139
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        64..101
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00884"
FT   DISULFID        89..153
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00884"
FT   VARIANT         27
FT                   /note="P -> R (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15959873"
FT                   /id="VAR_023127"
FT   VARIANT         54
FT                   /note="P -> L (in CFNS; dbSNP:rs104894801)"
FT                   /evidence="ECO:0000269|PubMed:15124102,
FT                   ECO:0000269|PubMed:15959873"
FT                   /id="VAR_023128"
FT   VARIANT         62
FT                   /note="I -> T (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15166289"
FT                   /id="VAR_023129"
FT   VARIANT         98
FT                   /note="L -> S (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15166289"
FT                   /id="VAR_023130"
FT   VARIANT         111
FT                   /note="T -> I (in CFNS; dbSNP:rs104894796)"
FT                   /evidence="ECO:0000269|PubMed:15124102"
FT                   /id="VAR_023131"
FT   VARIANT         115
FT                   /note="Q -> P (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15166289"
FT                   /id="VAR_023132"
FT   VARIANT         119
FT                   /note="P -> H (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15166289,
FT                   ECO:0000269|PubMed:15959873"
FT                   /id="VAR_023133"
FT   VARIANT         119
FT                   /note="P -> S (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15959873"
FT                   /id="VAR_023134"
FT   VARIANT         119
FT                   /note="P -> T (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15166289"
FT                   /id="VAR_023135"
FT   VARIANT         137
FT                   /note="T -> A (in CFNS; dbSNP:rs2080471329)"
FT                   /evidence="ECO:0000269|PubMed:15959873"
FT                   /id="VAR_023136"
FT   VARIANT         138
FT                   /note="S -> F (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15959873"
FT                   /id="VAR_023137"
FT   VARIANT         151
FT                   /note="G -> S (in CFNS; dbSNP:rs28936069)"
FT                   /evidence="ECO:0000269|PubMed:15166289,
FT                   ECO:0000269|PubMed:15959873"
FT                   /id="VAR_023138"
FT   VARIANT         151
FT                   /note="G -> V (in CFNS; dbSNP:rs28936070)"
FT                   /evidence="ECO:0000269|PubMed:15166289"
FT                   /id="VAR_023139"
FT   VARIANT         153
FT                   /note="C -> S (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15959873"
FT                   /id="VAR_023140"
FT   VARIANT         153
FT                   /note="C -> Y (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15959873"
FT                   /id="VAR_023141"
FT   VARIANT         154
FT                   /note="R -> H (in dbSNP:rs146636295)"
FT                   /evidence="ECO:0000269|PubMed:15166289"
FT                   /id="VAR_023142"
FT   VARIANT         155
FT                   /note="T -> P (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15166289"
FT                   /id="VAR_023143"
FT   VARIANT         158
FT                   /note="M -> I (in CFNS; dbSNP:rs28935170)"
FT                   /evidence="ECO:0000269|PubMed:15166289"
FT                   /id="VAR_023144"
FT   VARIANT         158
FT                   /note="M -> V (in CFNS; dbSNP:rs28936071)"
FT                   /evidence="ECO:0000269|PubMed:15166289"
FT                   /id="VAR_023145"
FT   VARIANT         172
FT                   /note="T -> M (in dbSNP:rs7889678)"
FT                   /id="VAR_059256"
FT   VARIANT         182
FT                   /note="S -> R (in CFNS)"
FT                   /evidence="ECO:0000269|PubMed:15959873"
FT                   /id="VAR_023146"
FT   VARIANT         189
FT                   /note="V -> A (in dbSNP:rs16989105)"
FT                   /id="VAR_023147"
FT   MUTAGEN         260..273
FT                   /note="Missing: The intracellular domain peptide fails to
FT                   localize to the nucleus."
FT                   /evidence="ECO:0000269|PubMed:16930449"
FT   MUTAGEN         344..346
FT                   /note="Missing: No effect on gamma-secretase mediated
FT                   proteolysis of the C-terminal fragment."
FT                   /evidence="ECO:0000269|PubMed:16930449"
SQ   SEQUENCE   346 AA;  38007 MW;  473DD2F1A5BF89DE CRC64;
     MARPGQRWLG KWLVAMVVWA LCRLATPLAK NLEPVSWSSL NPKFLSGKGL VIYPKIGDKL
     DIICPRAEAG RPYEYYKLYL VRPEQAAACS TVLDPNVLVT CNRPEQEIRF TIKFQEFSPN
     YMGLEFKKHH DYYITSTSNG SLEGLENREG GVCRTRTMKI IMKVGQDPNA VTPEQLTTSR
     PSKEADNTVK MATQAPGSRG SLGDSDGKHE TVNQEEKSGP GASGGSSGDP DGFFNSKVAL
     FAAVGAGCVI FLLIIIFLTV LLLKLRKRHR KHTQQRAAAL SLSTLASPKG GSGTAGTEPS
     DIIIPLRTTE NNYCPHYEKV SGDYGHPVYI VQEMPPQSPA NIYYKV
//
